then centrifuged at 10,000xg for 10 min at 4°C. Supernatant concentrations were normalized by measuring absorbance at 254 nm and a 0.125 volume of 10% Triton X-100 was gently added. Finally, ~600 µl of the clarified cell extracts were layered on 4.5-45% (w/v) sucrose gradients prepared in 25 mM Tris-HCl, pH 7.5, 150 mM KCl, 5 mM MgCl 2 , 1 mM DTT, and 0.5 mg/ml heparin, and then centrifuged for 2.5 h at 260,000xg in a Beckman SW41 rotor. Gradients were fractionated with an ISCO system while monitoring absorbance at 254 nm. For EDTA treatment, antibiotics were omitted and EDTA was added to 50 mM in the lysis buffer and to 10 mM in the sucrose gradients. RNA was purified from each fraction by two phenol/chloroform extractions and ethanol precipitation. Proteins were isolated from each fraction as previously described (6) and the resulting pellets dissolved in 8 M freshly prepared urea prior to being subject to SDS-PAGE and detection by immunoblotting. Fig. S1 . Structural organization of Chlamydomonas reinhardtii VIG1 (CrVIG1) and related proteins. (A) Schematic protein diagram of CrVIG1, indicating key domains, and its alignment with homologs from Arabidopsis thaliana (At4g17520), Drosophila melanogaster (DmVIG2), Homo sapiens (HsSERBP1) and Saccharomyces cerevisiae (ScStm1). Protein regions with enough sequence conservation for their alignment are indicated in green. RG/RGG, arginine/glycine-rich repeat domains. (B) Prediction of intrinsic protein disorder in CrVIG1 by MobiDB 3.0 (7) . The consensus disorder content (83%) integrates the outputs from the disorder predictors Dis-EMBL, ESpritz, IUPred and VSL2b (regions indicated in orange), as well as from GlobPlot, which predicts globular regions used as opposite of disorder (regions indicated in light blue). Anchor predicts binding regions located in disordered proteins that fold upon binding. FeSS predicts secondary structure (Helix or Sheet). DynaMine predicts backbone flexibility, where 1.0 means complete order (rigid, stable conformation) and 0 means fully random bond vector movement (flexible, highly dynamic). Seg and Pfilt predict low complexity regions. 
Sequence -CrVIG1
A B Fig. S2 . Unrooted maximum-likelihood tree showing the phylogenetic relationship among VIG1 homologs from diverse eukaryotes (excluding fungal proteins due to their lower overall sequence similarity). Protein sequences were aligned with Muscle and the tree was built by the PhyML method (Maximum Likelihood) using the Phylogeny.fr server (8) . Purple circles on branches indicate bootstrap values >70% based on 500 pseudoreplicates. The scale bar denotes 1 amino acid substitution per site. Protein sequences were extracted from the eggNOG orthology database (9) and their accession numbers are indicated on the tree preceded by the NCBI taxonomic identifier (except for those shaded in yellow). Sequences from Viridiplantae are indicated in green and those from metazoans are indicated in red. A sequence from the oomycete Albugo laibachii is indicated in blue. Protein names shaded in yellow correspond to: ..........t....t.h-R.stss...............p..tt....Wht.................... ..............................................t...t.hoht-a......................  ..............................t.tt............c.t.pphoLpEa.t...tph..........t.p.  ...........................t.. The panels display phase contrast images of the cells (Phase), immunolocalization of epitope-tagged VIG1, detected with an antibody conjugated to Alexa Fluor 488 (VIG1, green), DAPI staining of nuclear and organellar DNA (Dapi, blue), and the merged images (Merged). Representative images are shown, with the location of the nucleus indicated by N. Cells were grown to middle logarithmic phase in TAP medium, collected by centrifugation, and then processed for immunofluorescence microscopy. Aliquots of cells were also exposed to 42°C for 45 min (Heat shock) or incubated in the presence of 50 µg/ml cycloheximide for 2 h (Cycloheximide), prior to preparation for immunofluorescence microscopy. The distribution of AGO3/2, RPL37, and FLAG-CBP-VIG1 in the gradient fractions was analyzed by immunoblotting. The asterisk indicates a non-specific protein cross-reacting with the anti-AGO3/2 antibody. The expected location of monoribosomes (M) and polyribosomes (Poly) is shown above the blots. (B) Immunoblot analyses of AGO3 protein abundance in the indicated strains. Endogenous and transgenic AGO3/2 levels were examined with a rabbit polyclonal antibody raised against a C-terminal peptide from AGO3 (12) (upper panels). Since the corresponding sequence in AGO2 differs by only two amino acids, the antibody also cross-reacts with AGO2 (13) , but this protein is present at more than 10-fold lower abundance than AGO3 [compare AGO3 (EDO99188 = A8JAG8) vs. AGO2 (EDO99352 = A8J9T3) in PaxDb (14) ]. Coomassie-blue staining of an equivalent gel is shown as a control for similar loading of the lanes. The abundance of transgenic FLAG-tagged AGO3 was examined with an anti-FLAG antibody (bottom panels). Maa7-IR44, CC-124 transformed with an IR transgene designed to induce RNAi of MAA7 (encoding Tryptophan Synthase b subunit); Maa7-IR44(FLAG-AGO3)-56 and -8, transgenic strains of Maa7-IR44 transformed with FLAG-tagged AGO3; vig1(FLAG-AGO3)-31, VIG1 deletion mutant transformed with a FLAG-tagged AGO3 transgene. (C) Northern blot analyses of sRNAs isolated from the indicated strains and detected with probes specific for Chlamydomonas miRNAs. The same filter was reprobed with the U6 small nuclear RNA sequence as a control for equivalent loading of the lanes. (B) Immunoblot analyses of steady-state protein levels corresponding to Cytochrome c oxidase subunit II, protein IIb of split subunit (COX2B, encoded by Cre01.g049500), 40S ribosomal protein S14 (RPS14, encoded by Cre11.g480150), and Ribulose-1,5-bisphosphate carboxylase/oxygenase small subunits (RBCS1 and RBCS2, encoded by Cre02.g120100 and Cre02.g120150, respectively). None of the genes encoding these proteins has been identified as a miRNA target in C. reinhardtii by us (15, 16) or others (17) . ribosomal subunit) and may play a minor (non-essential) role(s) in modulating ribosome function/structure under normal growth conditions. Since the vig1 mutant is hypersensitive to exposure to cycloheximide, VIG1 may affect translation elongation (for instance, by influencing the activity/interactions of eEF3 like factors) and/or the accessibility of cycloheximide to its site of action at the ribosomal E-site. Alternatively, VIG1 may associate with translating ribosomes mainly in 'standby mode,' until it is required for clamping ribosomal subunits under nutrient starvation (18) . (B) Upon core (mi)RISC binding to a polyribosomeassociated target transcript, we hypothesize that it interacts (directly or indirectly) with VIG1 and switches this intrinsically disordered protein into an alternative conformational state leading to translational repression at multiple steps. Since VIG1 co-purifies with eIF3 subunits, which are known to associate with the 40S ribosomal subunit near RACK1 and the mRNA exit channel (18, 19) , it could conceivably affect the recruitment/interaction of components of the translation initiation machinery. Additionally, VIG1 bound to translating 80S ribosomes could inhibit translation elongation, as reported for its yeast homolog Stm1 (20, 21) , or even interfere with translation termination. In the Cryo-EM structures of non-translating 80S ribosomes (11, 22, 23) , VIG1 homologs occupy partially the mRNA entrance channel, interacting with the A and P sites, via conserved residues in the first part of the HABP4/SERBP1 domain (Fig. S6 ). This is unlikely to happen in translating ribosomes since it would result in steric clash with the mRNA. However, the C-terminus of the HABP4/SERBP1 domain (Fig. S6 , C-terminal residues indicated with asterisks) emerges from the mRNA channel to interact with ribosomal proteins eS10, eS12, and eS31 (11) . This Table S1 . FLAG-CBP-VIG1 associated proteins identified by mass spectrometry a Experiment number. An X indicates that the protein was detected in that experiment. b Peptides detected in more than one independent experiment are indicated in bold. 
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